Nirogy Therapeutics, Inc. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2013

Location

Natick MA US

Primary Industry

Biotechnology

About

Based in Massachusetts, US, and founded in 2013, Nirogyone Therapeutics develops novel small molecules to target cellular transport. The company was awarded a USD 2 million NIH/NCI SBIR grant to develop dual monocarboxylate transport inhibitors (dMCTi) for Triple Negative Breast Cancer (TNBC) in September 2020. Nirogy Therapeutics, Inc. has 4 employees across all its locations. The Company's products are SLCTs (Solute Carrier Transporters) which help to control the import and export of various molecules cells in our body and MCTs (Monocarboxylate Transporters) focus on blocking lactate export, which kills cancer cells. Nirogy Therapeutics plans to use the proceeds to advance its drug discovery platform to generate a pipeline of small-molecule drugs designed to target the solute carrier family of transporter proteins (SLCTs) embedded in the cell membrane.

Current Investors

Sante Ventures, Sporos Bioventures

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals, Pharmaceuticals

Website

www.nirogytx.com

Company Stage

Series A

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.